Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PTPRE | P23469 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30287480 | 1.00 | POLB (0.74) | POLBMAPTALDH1A1HPGDRAB9A | |
| SCHEMBL3729107 | 0.84 | MAPT (0.78) | POLBMAPTALDH1A1HPGDRAB9A | |
| SCHEMBL3729052 | 0.81 | HTT (0.74) | POLBMAPTALDH1A1HPGDRAB9A | |
| SCHEMBL3736372 | 0.81 | MAPT (0.61) | POLBMAPTALDH1A1HPGDRAB9A | |
| SCHEMBL30282807 | 0.81 | HTT (0.74) | POLBMAPTALDH1A1HPGDRAB9A | |
| SCHEMBL5446313 | 0.81 | RAB9A (0.66) | POLBMAPTALDH1A1HPGDRAB9A | |
| SCHEMBL3728335 | 0.79 | MAPT (0.62) | POLBMAPTALDH1A1HPGDRAB9A | |
| SCHEMBL3723685 | 0.79 | MAPT (0.58) | POLBMAPTALDH1A1HPGDRAB9A | |
| SCHEMBL11324576 | 0.78 | POLB (0.61) | POLBMAPTALDH1A1HPGDKDM4E | |
| SCHEMBL3729134 | 0.78 | MAPT (0.57) | POLBMAPTALDH1A1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023067515-A1 | THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20100120669-A1 | THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE | BOUILLOT ANNE MARIE JEANNE | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120669-A1 | THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE | SCD, SCD5, FADS2 | POLB 3408/4885MAPT 2890/4885ALDH1A1 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.